Get the plan’s answer in writing.

Ask about the plan’s conditions

Medicare calls its prescription medicine insurance Part D.

Federal law still kept weight-loss use outside basic Part D insurance when checked September 26, 2026.

A medicine could still qualify for Part D payment when used for another accepted medical reason, such as diabetes.

The formulary is where the plan names its covered medicines.

Prior authorization means a request must reach the plan for approval before the pharmacy fills it.

The plan’s formulary and prior authorization can still determine whether it pays.

Ask for a response tied to your own plan. Record the exact product and the use discussed, rather than a general answer about weight care.

Separate help with some weight-loss medicines

The Bridge is Medicare’s temporary arrangement for certain weight-loss medicines; its full name is Medicare GLP-1 Bridge.

Some medicines act like GLP-1, one of the body’s chemical messengers affecting appetite and blood sugar.

CMS, the agency running Medicare, said on September 26, 2026 that people who qualified for the Bridge paid $50 for a month’s medicine.

The word copay names your own share of a bill.

July 1, 2026 was the Bridge’s launch date; December 31, 2027 was its planned finish, with bills handled separately from ordinary Part D insurance.

During 2026, a central service handled Bridge approval requests and payments to pharmacies, instead of the usual Part D payment process.

Ask your pharmacy what details it needs to bill the Bridge before expecting the price at the counter.

The Bridge’s $50 monthly payment did not reduce the amount left before you reached your usual Part D yearly spending limit.

Reaching that yearly limit did not remove the Bridge payment, and people on low incomes received no extra help with this copay.

Age, health, insurance plan and the exact medicine all affected who could use the Bridge, under the September 26, 2026 rules.

Only orforglipron (Foundayo), semaglutide (Wegovy tablets or injection), and tirzepatide (Zepbound in the KwikPen device) were included.

Zepbound vials and single-dose pens were excluded; the named pen device mattered.

What to ask about qualifying for the Bridge

The programme’s minimum age was 18.

For insurance, you needed either a standalone Part D drug plan or Medicare Advantage that included medicine cover and was accepted by the programme.

Use your health and weight at the start of GLP-1 treatment for these checks; the programme rules were read September 26, 2026.

The rules use a number called BMI, worked out from height and weight. Ask your doctor which of these groups fits your medical record:

• One group had a BMI of at least 35.
• Another group had a BMI starting at 30, alongside a specified heart, blood-pressure or kidney condition.
• The group starting at BMI 27 included people with pre-diabetes, peripheral artery disease with symptoms, a past stroke, or a past heart attack.

Pre-diabetes describes raised blood sugar that has not reached the diabetes range. Peripheral artery disease means narrowed arteries, often in the legs.

For the middle group, ask your doctor to check the exact diagnosis and severity in the CMS eligibility page below. Naming a heart or kidney problem alone is not enough.

Type 2 diabetes and certain sleep-breathing or liver conditions ruled out the Bridge because those uses belonged with ordinary Part D insurance.

Ask your doctor to check those exclusions too; a liver diagnosis on its own does not settle the answer.

A GLP-1 medicine already paid for by Part D during 2026 also ruled out Bridge use in 2026.

The prescription needed advance approval, and treatment had to include continued work on structured eating plans and physical activity.

Bring the CMS eligibility list to whoever writes the prescription. Ask them to check it against your health and insurance details before you count on help.